⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 12, 2024Open Access

TABLE 3 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Pamela N. Münster Nicholas Iannotti Daniel C. Cho John M. Kirkwood Liza C. Villaruz Geoffrey T. Gibney F. Stephen Hodi Niharika B. Mettu Mark Jones Jill Bowman Michael Smith Mani Lakshminarayanan Steven O’Day

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Tumor response by RECIST (full analysis set)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Münster et al. (2024) studied this question.

synapsesocial.com/papers/68e746e5b6db6435876c0601 https://doi.org/10.1158/2767-9764.24866711.v2

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Data from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study2024
2TABLE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies2024
3TABLE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies2024
4Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
5Supplementary Figure S7 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer2024